Lite Strategy, Inc. Increase (Decrease) in Accounts Receivable
Lite Strategy, Inc. (LITS) reported Increase (Decrease) in Accounts Receivable of $0 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-11-14
- Lite Strategy, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-03-31 was $0.00.
- Lite Strategy, Inc. increase (decrease) in accounts receivable for the quarter ending 2021-12-31 was -$10.00M.
- Lite Strategy, Inc. increase (decrease) in accounts receivable for the quarter ending 2021-09-30 was $10.00M.
- Lite Strategy, Inc. increase (decrease) in accounts receivable for fiscal 2021 was $4.72M, a 101.28% increase from fiscal 2020.
- Lite Strategy, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $2.35M, a 1079.40% increase from fiscal 2019.
- Lite Strategy, Inc. increase (decrease) in accounts receivable for fiscal 2019 was $199.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | ||||
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-05-23 | -$10.00M derived: sum of 2 quarters · filed 2022-05-23 | $0.00 10-Q · filed 2022-05-23 | $25.14M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-12-31 | -$10.00M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-05-23 | $0.00 10-Q/A · filed 2022-05-23 | $25.14M derived: sum of 3 quarters · filed 2022-11-14 | $25.14M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-09-30 | $10.00M 10-Q · filed 2022-11-14 | $35.14M derived: sum of 2 quarters · filed 2022-11-14 | $35.14M derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $25.14M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-05-23 | $25.14M derived: sum of 2 quarters · filed 2022-05-23 | $4.72M 10-K/A · filed 2022-05-23 | ||
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-05-23 | -$20.42M 10-Q · filed 2022-05-23 | |||
| 2020-12-31 | -$20.42M 10-Q/A · filed 2022-05-23 | $20.42M 10-Q · filed 2022-02-10 | |||
| 2020-06-30 | $2.35M 10-K/A · filed 2022-05-23 | ||||
| 2019-06-30 | $199.00K 10-K/A · filed 2022-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |